Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel
Jan Borén,M. John Chapman,M. John Chapman,Ronald M. Krauss,Chris J. Packard,Jacob F. Bentzon,Jacob F. Bentzon,Christoph J. Binder,Mat J.A.P. Daemen,Linda L. Demer,Robert A. Hegele,Stephen J. Nicholls,Børge G. Nordestgaard,Gerald F. Watts,Gerald F. Watts,Eric Bruckert,Sergio Fazio,Brian A. Ference,Brian A. Ference,Ian D. Graham,Jay D. Horton,Ulf Landmesser,Ulrich Laufs,Luis Masana,Gerard Pasterkamp,Frederick J. Raal,Kausik K. Ray,Heribert Schunkert,Marja-Riitta Taskinen,Bart van de Sluis,Olov Wiklund,Lale Tokgozoglu,Alberico L. Catapano,Henry N. Ginsberg +33 more
TLDR
In this paper, the authors proposed a method to solve the problem of the problem: this paper ] of "uniformity" of the distribution of data points in the data set.Abstract:
Abstractread more
Citations
More filters
Journal ArticleDOI
The changing landscape of atherosclerosis.
TL;DR: In this article, the authors review the evidence and discuss its implications for understanding of atherosclerosis, and examine its implications in the treatment of cardiovascular disease. But they do not discuss the role of the bone marrow in the pathogenesis of the disease.
Journal ArticleDOI
Saturated Fats and Health: A Reassessment and Proposal for Food-based Recommendations: JACC State-of -the-Art Review
Arne Astrup,Faidon Magkos,Dennis M. Bier,J. Thomas Brenna,Marcia C de Oliveira Otto,James O. Hill,Janet C. King,Andrew Mente,Jose M. Ordovas,Jeff S. Volek,Salim Yusuf,Ronald M. Krauss +11 more
TL;DR: Whole-fat dairy, unprocessed meat, eggs and dark chocolate are SFA-rich foods with a complex matrix that are not associated with increased risk of CVD, and the totality of available evidence does not support further limiting the intake of such foods.
Journal ArticleDOI
NAFLD and cardiovascular diseases: a clinical review.
Philipp Kasper,Anna Martin,Sonja Lang,Fabian Kütting,Tobias Goeser,Münevver Demir,Hans-Michael Steffen +6 more
TL;DR: The underlying pathophysiological mechanisms linking NAFLD and CVD are described, the role ofNAFLD as a metabolic dysfunction associated cardiovascular risk factor is discussed, and common cardiovascular manifestations in NAFLd patients are focused on.
Journal ArticleDOI
Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society
Henry N. Ginsberg,Chris J. Packard,M. John Chapman,Jan Borén,Carlos A. Aguilar-Salinas,Maurizio Averna,Brian A. Ference,Daniel Gaudet,Robert A. Hegele,Sander Kersten,Gary F. Lewis,Alice H. Lichtenstein,Philippe Moulin,Børge G. Nordestgaard,Børge G. Nordestgaard,Alan T. Remaley,Bart Staels,Erik S.G. Stroes,Marja-Riitta Taskinen,Lale Tokgozoglu,Anne Tybjærg-Hansen,Jane K Stock,Alberico L. Catapano +22 more
TL;DR: In this paper, a conceptual framework for the generation of remnants due to dysregulation of TRL production, lipolysis, and remodelling, as well as clearance of remnant lipoproteins from the circulation, and challenges in defining, quantifying, and assessing the atherogenic properties of remnant particles.
Journal ArticleDOI
Overview of OxLDL and Its Impact on Cardiovascular Health: Focus on Atherosclerosis.
Anastasia V. Poznyak,Nikita G. Nikiforov,Alexander M Markin,Dmitry A. Kashirskikh,Veronika A. Myasoedova,E. Gerasimova,Alexander N. Orekhov +6 more
TL;DR: In this paper, the role of oxLDL in atherosclerosis development on different levels is discussed, and it suggests that LDL particles undergo numerous modifications that change their size, density and chemical properties within the blood flow and vascular wall.
References
More filters
Journal ArticleDOI
Inflammation in atherosclerosis
TL;DR: The new appreciation of the role of inflammation in atherosclerosis provides a mechanistic framework for understanding the clinical benefits of lipid-lowering therapies and unravelling the details of inflammatory pathways may eventually furnish new therapeutic targets.
Journal ArticleDOI
Inflammation, Atherosclerosis, and Coronary Artery Disease
TL;DR: The evidence is recounted that atherosclerosis, the main cause of CAD, is an inflammatory disease in which immune mechanisms interact with metabolic risk factors to initiate, propagate, and activate lesions in the arterial tree.
Journal ArticleDOI
Beyond cholesterol, modifications of low-density lipoprotein that increase its atherogenicity
Journal ArticleDOI
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Paul M. Ridker,Brendan M. Everett,Tom Thuren,Jean G. MacFadyen,William Chang,Christie M. Ballantyne,Francisco H. Fonseca,Jose C. Nicolau,Wolfgang Koenig,Stefan D. Anker,John J.P. Kastelein,Jan H. Cornel,Prem Pais,Daniel Pella,Jacques Genest,Renata Cifkova,Alberto J. Lorenzatti,Tamás Forster,Zhanna Kobalava,Luminita Vida-Simiti,Marcus Flather,Hiroaki Shimokawa,Hisao Ogawa,Mikael Dellborg,Paulo Roberto Ferreira Rossi,Roland P.T. Troquay,Peter Libby,Robert J. Glynn +27 more
TL;DR: Antiinflammatory therapy targeting the interleukin‐1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid‐level lowering.
Journal ArticleDOI
Inflammation in Atherosclerosis
TL;DR: The discovery of the immune basis of allograft arteriosclerosis demonstrated that inflammation per se can drive arterial hyperplasia, even in the absence of traditional risk factors.
Related Papers (5)
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular riskThe Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
François Mach,Colin Baigent,Alberico L. Catapano,Konstantinos C. Koskinas,Manuela Casula,Lina Badimon,M. John Chapman,Guy De Backer,Victoria Delgado,Brian A. Ference,Ian D. Graham,Alison Halliday,Ulf Landmesser,Borislava Mihaylova,Terje R. Pedersen,Gabriele Riccardi,Dimitrios J. Richter,Marc S. Sabatine,Marja-Riitta Taskinen,Lale Tokgozoglu,Olov Wiklund,Christian Mueller,Heinz Drexel,Victor Aboyans,Alberto Corsini,Wolfram Doehner,Michel Farnier,Bruna Gigante,Meral Kayıkçıoğlu,Goran Krstacic,Ekaterini Lambrinou,Basil S. Lewis,Josep Masip,Philippe Moulin,Steffen E. Petersen,Anna Sonia Petronio,Massimo F Piepoli,Xavier Pintó,Lorenz Räber,Kausik K. Ray,Željko Reiner,Walter F Riesen,Marco Roffi,Jean-Paul Schmid,Evgeny Shlyakhto,Iain A. Simpson,Erik S.G. Stroes,Isabella Sudano,Alexandros D Tselepis,Margus Viigimaa,Cecile Vindis,Alexander Vonbank,Michal Vrablik,Mislav Vrsalovic,José Luis Zamorano,Jean-Philippe Collet,Stephan Windecker,Veronica Dean,Donna Fitzsimons,Chris P Gale,Diederick E. Grobbee,Sigrun Halvorsen,Gerhard Hindricks,Bernard Iung,Peter Jüni,Hugo A. Katus,Christophe Leclercq,Maddalena Lettino,Béla Merkely,Miguel Sousa-Uva,Rhian M. Touyz,Djamaleddine Nibouche,Parounak H. Zelveian,Peter Siostrzonek,Ruslan Najafov,Philippe van de Borne,Belma Pojskic,Arman Postadzhiyan,Lambros Kypris,Jindřich Špinar,Mogens Lytken Larsen,Hesham Salah Eldin,Timo E. Strandberg,Jean Ferrières,Rusudan Agladze,Ulrich Laufs,Loukianos S. Rallidis,Laszlo Bajnok,Thorbjorn Gudjonsson,Vincent Maher,Yaakov Henkin,Michele Massimo Gulizia,Aisulu Mussagaliyeva,Gani Bajraktari,Alina Kerimkulova,Gustavs Latkovskis,Omar Hamoui,Rimvydas Šlapikas,Laurent Visser,P. Dingli,Victoria Ivanov,Aneta Boskovic,Mbarek Nazzi,Frank L.J. Visseren,Irena Mitevska,Kjetil Retterstøl,Piotr Jankowski,Ricardo Fontes-Carvalho,Dan Gaita,Marat V. Ezhov,Marina Foscoli,Vojislav Giga,Daniel Pella,Zlatko Fras,Leopoldo Pérez de Isla,Emil Hagström,Roger Lehmann,Leila Abid,Oner Ozdogan,Olena Mitchenko,Riyaz S. Patel +120 more
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
Brian A. Ference,Henry N. Ginsberg,Ian D. Graham,Kausik K. Ray,Chris J. Packard,Eric Bruckert,Robert A. Hegele,Ronald M. Krauss,Frederick J. Raal,Heribert Schunkert,Gerald F. Watts,Jan Borén,Sergio Fazio,Jay D. Horton,Luis Masana,Stephen J. Nicholls,Børge G. Nordestgaard,Børge G. Nordestgaard,Bart van de Sluis,Marja-Riitta Taskinen,Lale Tokgozoglu,Ulf Landmesser,Ulf Landmesser,Ulf Landmesser,Ulrich Laufs,Olov Wiklund,Olov Wiklund,Jane K Stock,M. John Chapman,Alberico L. Catapano +29 more
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
Scott M. Grundy,Neil J. Stone,Alison L. Bailey,Craig A. Beam,Kim K. Birtcher,Roger S. Blumenthal,Lynne T. Braun,Sarah D. de Ferranti,Joseph Faiella-Tommasino,Daniel E. Forman,Ronald N. Goldberg,Paul A. Heidenreich,Mark A. Hlatky,Daniel W. Jones,Donald M. Lloyd-Jones,Nuria Lopez-Pajares,Chiadi E Ndumele,Carl E. Orringer,Carmen A. Peralta,Joseph J. Saseen,Sidney C. Smith,Laurence S. Sperling,Salim S. Virani,Joseph Yeboah +23 more